How Liraglutide works
A daily GLP-1 injection approved for weight management and type 2 diabetes.
Also called: Saxenda, Victoza, NN2211, Xultophy component.
GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.
It copies a gut hormone that helps you feel full. It increases insulin release when blood sugar is high, lowers glucagon, and slows food leaving the stomach.
- GLP-1 receptor: Increases glucose-dependent insulin release, lowers glucagon and slows stomach emptying.
Half-life: About 13 hours after subcutaneous injection.
Related to Liraglutide
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Dulaglutide: A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
- Exenatide: An older GLP-1 with twice-daily and weekly forms, now widely discontinued.
Sources
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026, 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Consensus-based clinical and research recommendations for use of glucagon-like peptide-1 receptor agonists in the context of eating disorders: a modified Delphi study., Keshen A et al. · World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026
- DailyMed - SAXENDA- liraglutide injection, solution, 2026
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA · 2026
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, FDA · 2026
- FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications, FDA · 2026
- GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases, 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- TRULICITY, 2026
- Weight Loss Drugs: What athletes need to know about GLP-1s, USADA · 2026
- DailyMed - VICTOZA- liraglutide injection, 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.